ID   P388 Pr8/22
AC   CVCL_4276
SY   Pr8/22; PR8/22; P388R
DR   CLO; CLO_0008482
DR   CancerTools; 153248
DR   ECACC; 93112518
DR   Wikidata; Q54937249
DR   Ximbio; 153248
RX   PubMed=6627597;
RX   PubMed=7917900;
CC   Doubling time: 28.5 hours (PubMed=6627597).
CC   Selected for resistance to: ChEBI; CHEBI_41977; Daunorubicin (Daunomycin).
CC   Transformant: ChEBI; CHEBI_34342; 3-methylcholanthrene (3-MC; 20-methylcholanthrene; 20-MC; MCA).
CC   Discontinued: ECACC; 93112518; true.
CC   Breed/subspecies: DBA/2.
DI   NCIt; C21602; Mouse lymphoma
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_D640 ! P388/S
SX   Female
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 14
//
RX   PubMed=6627597; DOI=10.1007/BF00254258;
RA   McGown A.T., Ward T.H., Fox B.W.;
RT   "Comparative studies of the uptake of daunorubicin in sensitive and
RT   resistant P388 cell lines by flow cytometry and biochemical extraction
RT   procedures.";
RL   Cancer Chemother. Pharmacol. 11:113-116(1983).
//
RX   PubMed=7917900; DOI=10.1038/bjc.1994.353; PMCID=PMC2033429;
RA   Prendiville J.A., McGown A.T., Gescher A.J., Dickson A.J., Courage C.,
RA   Pettit G.R., Crowther D., Fox B.W.;
RT   "Establishment of a murine leukaemia cell line resistant to the
RT   growth-inhibitory effect of bryostatin 1.";
RL   Br. J. Cancer 70:573-578(1994).
//